MedTrace Logo

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

NCT00349193 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 306

Last updated 2011-04-08

No results posted yet for this study

Summary

Teva is developing laquinimod tablets as a new oral treatment for MS. Laquinimod has immunomodulating properties. In a previous clinical study laquinimod showed evidence of biological activity by reducing the number of acute brain lesions.

The duration of the current study is 36 weeks.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

laquinimod 0.3

laquinimod 0.3mg

DRUG

laquinimod 0.6

laquinimod 0.6mg

OTHER

Placebo

Blinded Placebo

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Prof. Giancarlo Comi · Teva Pharmaceutical Industries, Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2006-06-30
Completion
2006-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00349193 on ClinicalTrials.gov